Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Distinct neurostructural, cognitive, and neuropsychiatric associations of plasma p-tau217, and Aβ42/40 in Parkinson's disease and aging cohorts.

Frontiers in aging neuroscience·2026
Same author

Longitudinal Decline in Electrochemical Skin Conductance Reflects Disease Progression in Multiple System Atrophy.

European journal of neurology·2026
Same author

Plasma p-tau217 Versus p-tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease-Related Neurostructural Changes and Cognitive Function.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Natural history and 12-month progression of multiple system atrophy in a Chinese cohort.

BMC neurology·2026
Same author

Correction: Heart rate variability provides prognostic value in multiple system atrophy.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same journal

[Rehabilitation in the elderly subject with Parkinson's disease].

Psychologie & neuropsychiatrie du vieillissement·2013
Same journal

[Specificities of the treatment of Parkinson's disease in the elderly].

Psychologie & neuropsychiatrie du vieillissement·2013
Same journal

[Parkinson's disease dementia and Lewy body dementia].

Psychologie & neuropsychiatrie du vieillissement·2013
Same journal

[Cognitive disorders in Parkinson's disease without dementia].

Psychologie & neuropsychiatrie du vieillissement·2013
Same journal

[Psychotic symptoms in Parkinson's disease].

Psychologie & neuropsychiatrie du vieillissement·2013
Same journal

[Parkinson's disease: psychological and behavioral disorders].

Psychologie & neuropsychiatrie du vieillissement·2013
See all related articles

Related Experiment Video

Updated: Jun 9, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

[Multiple system atrophy].

Nathalie Damon-Perrière1, François Tison, Wassilios G Meissner

  • 1Service de neurologie, Centre de référence national maladie rare atrophie multisystématisée, CHU de Bordeaux, Hôpital du Haut-Lévêque, Pessac.

Psychologie & Neuropsychiatrie Du Vieillissement
|August 27, 2010
PubMed
Summary
This summary is machine-generated.

Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative disease. Diagnosis relies on clinical symptoms and imaging, with supportive care improving quality of life.

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Experiment Videos

Last Updated: Jun 9, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Area of Science:

  • Neuroscience
  • Neurology
  • Pathology

Context:

  • Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder with unknown etiology.
  • It is the most frequent disorder among atypical parkinsonism, affecting 2-5 per 100,000 inhabitants.
  • Characterized by rapidly progressing clinical symptoms and a mean survival of 6-9 years.

Purpose:

  • To outline the diagnostic criteria for Multiple System Atrophy (MSA).
  • To describe the clinical presentation, diagnostic features, and management strategies for MSA.
  • To highlight the importance of supportive care in improving the quality of life for MSA patients.

Summary:

  • Diagnosis of MSA is based on revised 2008 consensus criteria, categorizing cases as "possible", "probable", or "definite".
  • Definite MSA requires post-mortem confirmation of specific neuropathological findings.
  • "Possible" and "probable" diagnoses rely on the presence and severity of parkinsonism, cerebellar dysfunction, autonomic failure, and pyramidal signs.
  • Brain MRI findings like putaminal atrophy, "hot cross bun sign", and MCP hyperintensities aid diagnosis.
  • Autonomic function testing (cardiovascular, urodynamic, anal sphincter EMG) is crucial for diagnosing autonomic failure.
  • While levodopa may offer limited benefit, specific therapies exist for autonomic dysfunction, and physical, speech, and occupational therapies are vital for symptom management and quality of life.

Impact:

  • Improved diagnostic accuracy for Multiple System Atrophy (MSA).
  • Enhanced understanding of MSA's clinical spectrum and progression.
  • Provides a framework for multidisciplinary management and supportive care strategies to improve patient outcomes and quality of life.